Cellzome awarded UK’s Technology Strategy Board grant as part of the Regenerative Medicine Programme
Three grants have been awarded this year which demonstrate the broad utility of Cellzome’s unique chemoproteomics platform
Advertisement
Cellzome announced the award of a grant by the UK government-backed Technology Strategy Board under its regenerative medicine Programme: “Tools and Technologies” for a project which will address the need for better characterisation of human stem cells. Cellzome will use its EpisphereTM technology in collaboration with Pfizer Ltd (Neusentis), the University of Sheffield and Plasticell Limited to identify protein fingerprints which are predictive of potentially deleterious changes in the stem cells. The project will be led by Cellzome and the funding will amount to €1.1M (GBP 0.9M) over a period of two years.
This is the third grant awarded this year that leverages Cellzome’s unique position in chemoproteomics and supports the company’s innovative approaches to drug discovery.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
New research data highlight the potential of Basilea's BAL101553 as a novel oncology drug candidate
E. coli more virulent when accompanied by beneficial bacteria
Genetic markers linking risk for type 2 diabetes and Alzheimer's identified
EyeTechCare raises EUR 7.5 million in a second funding round and speeds up its development
David Evans steps down as chairman of the board for Horizon Discovery
New clinical and preclinical data on Basilea's novel antibiotic BAL30072 against multidrug-resistant Gram-negative superbugs